Dr. O'Neil on Stemness Inhibitors for CRC Treatment

Bert O'Neil, MD
Published: Thursday, Mar 16, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Stemness inhibitors are one of the advances that are really exciting in the field, O'Neil says. This addresses the potential of the Wnt/β-catenin pathway, he adds. Researchers also have conducted a study with the stemness inhibitor napabucasin (BBI-608) in CRC where there seemed to be some signs of preliminary activity. This is currently now in an ongoing phase III study.

There have been other inhibitors being developed of the Wnt/β-catenin pathway, O'Neil says, adding that this is a novel concept for this landscape.
SELECTED
LANGUAGE


Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Stemness inhibitors are one of the advances that are really exciting in the field, O'Neil says. This addresses the potential of the Wnt/β-catenin pathway, he adds. Researchers also have conducted a study with the stemness inhibitor napabucasin (BBI-608) in CRC where there seemed to be some signs of preliminary activity. This is currently now in an ongoing phase III study.

There have been other inhibitors being developed of the Wnt/β-catenin pathway, O'Neil says, adding that this is a novel concept for this landscape.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x